Attovia Therapeutics (ATTO) raises upsized IPO on Nasdaq, extending biotech's 3-week streak. CEO Tao Fu's firm targets I&I with drugs ATTO-1310, ATTO-2306, ATTO-1091.
For the first time since the winter of 2025, the biotech industry is celebrating three consecutive weeks of initial public offerings.
Attovia Therapeutics, an immunology …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Attovia files for a Nasdaq IPO under ticker ATTO, becoming the third biotech to file this month after Scribe and Apnimed.
The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during…
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s…
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech…
Odyssey Therapeutics raised $279 million in an upsized IPO priced at $18 a share, with the autoimmune disease biotech set to…
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
